Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
KCNN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNN1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITPK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITPK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITPK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JAKMIP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JAKMIP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JAKMIP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ITM2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ITM2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ITM2B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
JKAMP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
JKAMP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of JKAMP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
HYKK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
HYKK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of HYKK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IKBKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IKBKB Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IKBKB sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
HIPK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
HIPK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of HIPK4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IPPK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IPPK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IPPK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IP6K2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IP6K2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IP6K2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GSK3B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GSK3B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GSK3B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GNE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GNE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of GNE sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →